The Life Sciences team advised COMPASS Pathways plc (Nasdaq: CMPS) on its initial public offering of 8,625,000 American Depositary Shares (“ADSs”) representing 8,625,000 ordinary shares at an initial public offering price of $17.00 per ADS, which includes 1,125,000 additional ADSs issued upon the exercise in full by the underwriters of their option to purchase additional ADSs. The total gross proceeds to COMPASS from the offering were $146.6 million.
COMPASS is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is pioneering the development of a new model of psilocybin therapy, in which the proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and COMPASS is currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America.
The Goodwin team was led by Mitch Bloom, Benjamin Marsh, and Sophie McGrath.
For more details, read the press release.
COMPASS is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is pioneering the development of a new model of psilocybin therapy, in which the proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and COMPASS is currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America.
The Goodwin team was led by Mitch Bloom, Benjamin Marsh, and Sophie McGrath.
For more details, read the press release.